Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides

Consensus porposal on the use of iodine-131 in hyperthyroidism and thyroid cancer A consensus meeting held by the Chilean Endocrinological Society reached to 22 consensus proposals on the use of iodine-131 in hyperthyroidism and thyroid cancer, that are reported in this paper. Some of these propos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Michaud Ch.,Patricio
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 1998
Materias:	Thyroid diseases goiter GravesÕ disease Thyrotoxicosis Thyroid neoplasms Iodine radioisotopes, therapeutic
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98871998000700015
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98871998000700015
record_format	dspace
spelling	oai:scielo:S0034-988719980007000151999-06-15Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroidesMichaud Ch.,Patricio Thyroid diseases goiter GravesÕ disease Thyrotoxicosis Thyroid neoplasms Iodine radioisotopes, therapeutic Consensus porposal on the use of iodine-131 in hyperthyroidism and thyroid cancer A consensus meeting held by the Chilean Endocrinological Society reached to 22 consensus proposals on the use of iodine-131 in hyperthyroidism and thyroid cancer, that are reported in this paper. Some of these propositions are: 1) Hyperthyroidism: A previous 131I uptake test must be performed. A calculated or an ablative dose should be administered. Hypothyroidism must be considered an objective rather than a complication. In patients with cardiovascular risk, normal thyroid function must be attained with propythioturacil. In cases of treatment failure, the dose should not be repeated before six months. It must be used with used with caution in children and teenagers. 2) Thyroid cancer: A iodine free diet is recommended prior to the therapeutic dose. A 100 mCi complementary ablative dose should be given after surgery, with a posterior exploration. This examination must not be done routinely, and if required, a 5 mCi dose should be used. For the treatment of metastases, a dose of 150 to 200 mCi is recommended. There is no radiation risk in hyperthyroidism or thyroid cancer. The only absolute contraindication is pregnancy. Recommendations for radiological protection are formulated. Hospitalization is suggested to protect other people from radiation exposure.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.126 n.7 19981998-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98871998000700015es10.4067/S0034-98871998000700015
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Thyroid diseases goiter GravesÕ disease Thyrotoxicosis Thyroid neoplasms Iodine radioisotopes, therapeutic
spellingShingle	Thyroid diseases goiter GravesÕ disease Thyrotoxicosis Thyroid neoplasms Iodine radioisotopes, therapeutic Michaud Ch.,Patricio Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
description	Consensus porposal on the use of iodine-131 in hyperthyroidism and thyroid cancer A consensus meeting held by the Chilean Endocrinological Society reached to 22 consensus proposals on the use of iodine-131 in hyperthyroidism and thyroid cancer, that are reported in this paper. Some of these propositions are: 1) Hyperthyroidism: A previous 131I uptake test must be performed. A calculated or an ablative dose should be administered. Hypothyroidism must be considered an objective rather than a complication. In patients with cardiovascular risk, normal thyroid function must be attained with propythioturacil. In cases of treatment failure, the dose should not be repeated before six months. It must be used with used with caution in children and teenagers. 2) Thyroid cancer: A iodine free diet is recommended prior to the therapeutic dose. A 100 mCi complementary ablative dose should be given after surgery, with a posterior exploration. This examination must not be done routinely, and if required, a 5 mCi dose should be used. For the treatment of metastases, a dose of 150 to 200 mCi is recommended. There is no radiation risk in hyperthyroidism or thyroid cancer. The only absolute contraindication is pregnancy. Recommendations for radiological protection are formulated. Hospitalization is suggested to protect other people from radiation exposure.
author	Michaud Ch.,Patricio
author_facet	Michaud Ch.,Patricio
author_sort	Michaud Ch.,Patricio
title	Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
title_short	Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
title_full	Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
title_fullStr	Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
title_full_unstemmed	Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
title_sort	proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides
publisher	Sociedad Médica de Santiago
publishDate	1998
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98871998000700015
work_keys_str_mv	AT michaudchpatricio proposiciondeconsensoparaelusodeyodo131eneltratamientodelatirotoxicosisyelcancerdeltiroides
_version_	1718435871065112576

Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides

Ejemplares similares